BioInnovation Institute selects 11 deep tech startups
Copenhagen-based BioInnovation Institute (BII) has welcomed 11 new deep tech startups into its flagship Venture Lab programme, each receiving €500,000 in funding alongside access to advanced laboratories, business acceleration and mentoring. The new cohort focuses on breakthrough solutions in human health, planetary health and emerging quantum technologies.
Strategic push in health and quantum innovation
The latest intake underlines BII’s ambition to bridge cutting-edge academic research and market-ready ventures. The selected startups include university spinouts developing 2D graphene-based materials and pioneering cardiac therapies such as Ibnova with its regenerative heart patches. These ventures target critical unmet needs in cardiovascular disease, advanced biomaterials and sustainable life science applications.
By combining equity funding with structured support, the programme aims to de-risk early-stage deep tech companies that typically face long development timelines and high capital requirements. Each startup will receive tailored guidance on regulatory strategy, intellectual property, clinical validation and go-to-market planning.
Venture Lab model: capital plus infrastructure
€500K per startup and access to top-tier labs
Under the Venture Lab model, each company secures €500,000 in non-dilutive or founder-friendly funding, enabling teams to extend their runway during crucial proof-of-concept and preclinical stages. In addition, BII provides shared access to high-spec laboratories, specialised equipment and technical support staff, resources that are often prohibitively expensive for early-stage teams.
Founders also benefit from a curated network of industry experts, venture capital investors and corporate partners active in healthtech, biotech and quantum innovation.
Strengthening the Nordic innovation ecosystem
The new cohort reinforces Copenhagen’s position as a growing hub for life sciences and deep tech entrepreneurship. By nurturing spinouts in fields such as graphene-enabled devices and regenerative medicine, BioInnovation Institute is helping to translate high-impact research into scalable companies that can address global health and sustainability challenges.
The 11 startups will progress through an intensive acceleration period, during which they are expected to refine their technology, validate business models and prepare for follow-on investment from institutional and strategic backers.